EIB investing $102M in UCB R&D pipeline in risk-sharing model
LONDON – The European Investment Bank (EIB) is to put in €75 million (US$101.8 million) to directly fund six research programs at pharma company UCB SA, as part of a new "at-risk co-development funding" instrument under which the bank will invest €24 billion in R&D projects over the next seven years.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST